BAX Stock Overview
Through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
Baxter International Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$29.50 |
| 52 Week High | US$44.01 |
| 52 Week Low | US$28.62 |
| Beta | 0.57 |
| 1 Month Change | -11.17% |
| 3 Month Change | -24.36% |
| 1 Year Change | -23.14% |
| 3 Year Change | -65.52% |
| 5 Year Change | -64.90% |
| Change since IPO | 2,154.33% |
Recent News & Updates
Recent updates
Is Baxter International Inc. (NYSE:BAX) Trading At A 49% Discount?
Sep 05
Baxter- Reiterating Our Buy Rating After A Promising Q2
Aug 07Baxter International (NYSE:BAX) Will Pay A Dividend Of $0.29
Aug 07Baxter International (NYSE:BAX) Has Affirmed Its Dividend Of $0.29
Jul 23Baxter: Why Investors Should Take Advantage Of The Low Valuation
Jul 16Little Excitement Around Baxter International Inc.'s (NYSE:BAX) Revenues
Jul 12Baxter International (NYSE:BAX) Has Affirmed Its Dividend Of $0.29
May 30Baxter International (NYSE:BAX) Is Due To Pay A Dividend Of $0.29
May 14Baxter International: Shares Too Cheap, EPS Growth Ahead With A Possible Spinoff
May 08Capital Allocation Trends At Baxter International (NYSE:BAX) Aren't Ideal
Apr 14Broyhill - Baxter International: Renal Care Spin-Off And Recent Revamp Should Provide Catalysts
Feb 23Baxter International's (NYSE:BAX) Dividend Will Be $0.29
Feb 20Here's Why Baxter International (NYSE:BAX) Has A Meaningful Debt Burden
Jan 28Baxter International (NYSE:BAX) Could Be Struggling To Allocate Capital
Jan 12Baxter International Inc.'s (NYSE:BAX) Prospects Need A Boost To Lift Shares
Dec 28Baxter International: A Cheap Big Pharma Stock With Improving Earnings And +3% Dividend Yield
Dec 12Should You Buy Baxter Or DaVita After The Fallout From The Ozempic Trial?
Oct 12Dividend Challengers Review: Baxter International
Aug 14Baxter International: Hillrom Acquisition Could Be A Tailwind For FCF
Jun 12Shareholder Returns
| BAX | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -2.7% | -1.5% | -2.4% |
| 1Y | -23.1% | 10.1% | 23.3% |
Return vs Industry: BAX underperformed the US Medical Equipment industry which returned 10.1% over the past year.
Return vs Market: BAX underperformed the US Market which returned 23.3% over the past year.
Price Volatility
| BAX volatility | |
|---|---|
| BAX Average Weekly Movement | 3.7% |
| Medical Equipment Industry Average Movement | 7.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BAX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BAX's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1931 | 60,000 | Joe Almeida | www.baxter.com |
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.
Baxter International Inc. Fundamentals Summary
| BAX fundamental statistics | |
|---|---|
| Market cap | US$15.06b |
| Earnings (TTM) | US$121.00m |
| Revenue (TTM) | US$15.06b |
124.5x
P/E Ratio1.0x
P/S RatioIs BAX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BAX income statement (TTM) | |
|---|---|
| Revenue | US$15.06b |
| Cost of Revenue | US$9.42b |
| Gross Profit | US$5.64b |
| Other Expenses | US$5.52b |
| Earnings | US$121.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.24 |
| Gross Margin | 37.47% |
| Net Profit Margin | 0.80% |
| Debt/Equity Ratio | 162.9% |
How did BAX perform over the long term?
See historical performance and comparisonDividends
2.3%
Current Dividend Yield487%
Payout RatioDoes BAX pay a reliable dividends?
See BAX dividend history and benchmarks| Baxter International dividend dates | |
|---|---|
| Ex Dividend Date | Nov 29 2024 |
| Dividend Pay Date | Jan 02 2025 |
| Days until Ex dividend | 23 days |
| Days until Dividend pay date | 11 days |
Does BAX pay a reliable dividends?
See BAX dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 01:53 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Baxter International Inc. is covered by 46 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Benjamin Yeoh | Atlantic Equities LLP |
| Daniel Owczarski | Avondale Partners |